The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma
Blood · 11.01.2024 · 143 (2) · 152-165
DOI: 10.1182/blood.2023021348 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Blood, erschienen am 11.01.2024. Verfasst von Pietro R Di Ciaccio und 37 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, The Canberra Hospital, Garran, ACT, Australia. Hauptthemen laut MEDLINE: Plasmablastic Lymphoma, HIV Infections, Epstein-Barr Virus Infections. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma associated with immunodeficiency, characterized by uncertain treatment approaches and an unfavorable prognosis. We conducted a multicenter, international, retrospective cohort study, aiming to characterize the clinical features, risk factors, and outcomes of patients with PBL. Data were collected from 22 institutions across 4 countries regarding patients diagnosed with PBL between 1 January 1999 and 31 December 2020. Survival risk factors were analyzed using both univariate and multivariate regression models. Overall survival (OS) was calculated using Kaplan-Meier statistics. First-line treatment regimens were stratified into standard- and higher-intensity regimens, and based on whether they incorporated a proteasome inhibitor (PI). A total of 281 patients (median age, 55 years) were included. Immunodeficiency of any kind was identified in 144 patients (51%), and 99 patients (35%) had HIV-positive results. The 5-year OS for the entire cohort was 36% (95% confidence interval, 30%-42%). In multivariate analysis, inferior OS was associated with Epstein-Barr virus–negative lymphoma, poor performance status, advanced stage, and bone marrow involvement. In an independent univariate analysis, the international prognostic index was associated with OS outcomes. Neither immunosuppression nor HIV infection, specifically, influenced OS. Among patients treated with curative intent (n = 234), the overall response rate was 72%. Neither the intensity of the treatment regimen nor the inclusion of PIs in first-line therapy was associated with OS. In this large retrospective study of patients with PBL, we identified novel risk factors for survival. PBL remains a challenging disease with poor long-term outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Haematology, The Canberra Hospital, Garran, ACT, Australia.
- College of Health and Medicine, Australian National University, Canberra, ACT, Australia.
- John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia.
- Department of Haematology, University College Hospital, London, United Kingdom.
- Centre for Lymphoid Cancer and Division of Medical Oncology, BC Cancer, University of British Columbia, Vancouver, BC, Canada.
- Department of Haematology, St James University Hospital, Leeds, United Kingdom.
ORCID-Profile: Pietro R Di Ciaccio, Alina S Gerrie, Mark Bower, Silvia Montoto, Pam McKay, Christopher P Fox, Samuel Milliken, Awachana Jiamsakul, Kim M Linton, Sunil Iyengar, David Kliman, Nicole Wong Doo, Matthew Ku, Rageshri Dhairyawan, Keir Pickard, Daniel Painter, Nada Hamad
Zitieren
APA
Di Ciaccio, P. R., Polizzotto, M. N., Cwynarski, K., Gerrie, A. S., Burton, C., Bower, M., Kuruvilla, J., Montoto, S., McKay, P., Fox, C. P., Milliken, S., Jiamsakul, A., Osborne, W., Collins, G. P., Manos, K., Linton, K. M., Iyengar, S., Kassam, S., Limei, M. P., …, & Hamad, N. (2024). The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma. Blood, 143(2), 152-165. https://doi.org/10.1182/blood.2023021348
Vancouver
Di Ciaccio PR, Polizzotto MN, Cwynarski K, Gerrie AS, Burton C, Bower M, et al. The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma. Blood. 2024;143(2):152-165. doi:10.1182/blood.2023021348
BibTeX
@article{DiCiaccio2024,
author = {Di Ciaccio, Pietro R and Polizzotto, Mark N and Cwynarski, Kate and Gerrie, Alina S and Burton, Catherine and Bower, Mark and Kuruvilla, John and Montoto, Silvia and McKay, Pam and Fox, Christopher P and Milliken, Samuel and Jiamsakul, Awachana and Osborne, Wendy and Collins, Graham P and Manos, Kate and Linton, Kim M and Iyengar, Sunil and Kassam, Shireen and Limei, Michelle Poon and Kliman, David and Wong Doo, Nicole and Watson, Anne-Marie and Fedele, Pasquale and Yannakou, Costas K and Hunt, Stewart and Ku, Matthew and Sehn, Laurie H and Smith, Alexandra and Renshaw, Hanna and Maxwell, Alice and Liu, Qin and Dhairyawan, Rageshri and Ferguson, Graeme and Pickard, Keir and Painter, Daniel and Thakrar, Nisha and Song, Kevin W and Hamad, Nada},
title = {The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma},
journal = {Blood},
year = {2024},
volume = {143},
number = {2},
pages = {152--165},
doi = {10.1182/blood.2023021348}
}
EUVIMED